Sandbox g12: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 16: | Line 16: | ||
:* '''Drugs with conditional TdP risk''' | :* '''Drugs with conditional TdP risk''' | ||
::* [[Amantadine|Amantadine (Symmetrel®, Symadine®)]] | |||
::* [[Hydroxychloroquine|Hydroxychloroquine (Plaquenil®, Quineprox®)]] | |||
::* [[Itraconazole|Itraconazole (Sporanox®, Onmel®)]] | ::* [[Itraconazole|Itraconazole (Sporanox®, Onmel®)]] | ||
::* [[Ketoconazole|Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)]] | |||
::* [[Metronidazole|Metronidazole (Flagyl® and many others)]] | |||
::* [[Nelfinavir|Nelfinavir (Viracept®)]] | |||
::* [[Posaconazole|Posaconazole (Noxafil®, Posamol®)]] | |||
::* [[Quinine sulfate|Quinine sulfate (Qualaquin®)]] | |||
::* [[Ritonavir|Ritonavir (Norvir®)]] | |||
::* [[Telaprevir|Telaprevir (Incivek®, Incivo®)]] | |||
::* [[Voriconazole|Voriconazole (VFend®)]] | |||
:* '''Drugs to be avoided by congenital Long QT''' | :* '''Drugs to be avoided by congenital Long QT''' | ||
Revision as of 21:47, 31 May 2015
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Drugs with possible TdP risk
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Amantadine (Symmetrel®, Symadine®)
- Hydroxychloroquine (Plaquenil®, Quineprox®)
- Itraconazole (Sporanox®, Onmel®)
- Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)
- Metronidazole (Flagyl® and many others)
- Nelfinavir (Viracept®)
- Posaconazole (Noxafil®, Posamol®)
- Quinine sulfate (Qualaquin®)
- Ritonavir (Norvir®)
- Telaprevir (Incivek®, Incivo®)
- Voriconazole (VFend®)
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable/minimal risk for QT interval prolongation/TdP)